Loading
companiesCompany
ScreenPoint Medical
Radboud University spin-out whose Transpara software is the AI reader tested in the MASAI screening trial.
Overview
ScreenPoint's Transpara is CE-marked and FDA-cleared for 2D and 3D mammography and is the breast screening AI with the most published trial evidence, used in MASAI (Sweden) and in Danish and German programmes. The company's founders come from the Nijmegen computer-aided detection group that ran the DREAM mammography challenge.
Headquarters
Nijmegen, NL
Scorecard
All companies#365of 1244 companies, score 10
- approved products +6
- modalities +2
- regions +2
1 approved, 0 in phase 3, 0 earlier, 0 targets, 0 registry studies. Formula on the scorecards page.
Type
Stage
Startup
Website
Founded
2014
ApprovedAI mammography detection and decision-support software
Transpara · Transpara
The breast screening AI tested in Sweden's MASAI trial, where AI-supported reading found more cancers and nearly halved the radiologists' workload.
Similar pages
- CompanyTherapixel
Shares Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer.
- CompanyVara
Shares Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer.
- CompanyiCAD (RadNet)
Shares Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer.
- CompanyVolpara Health
Shares Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer.
- PersonKristina Lång
Shares Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer.
- TreatmentProFound AI (iCAD)
Shares Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer.
- PersonConstance D. Lehman
Shares Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer.
- CompanyKheiron Medical Technologies
Shares Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer.
cancers
fronts
technologies
drugs
ApprovedAI mammography detection and decision-support software
Transpara · Transpara
trials
Software in use
The software of oncology →Commercial and regulated products that this organisation sells. Each card says what is behind it: a regulator's database, the literature, a public body's list, or only the company's own words. Listing is not endorsement, and a clearance is a regulatory fact, not a clinical one.
A mammography reading algorithm used in screening programmes, scoring each examination and marking suspicious findings for the reader.